Welcome to our dedicated page for Neurocrine Biosciences news (Ticker: NBIX), a resource for investors and traders seeking the latest updates and insights on Neurocrine Biosciences stock.
Neurocrine Biosciences Inc (NBIX) is a leading neuroscience-focused biopharmaceutical company developing innovative therapies for complex neurological, endocrine, and neuropsychiatric disorders. This comprehensive news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives driving the company's mission to address unmet medical needs.
Stay informed with verified updates spanning FDA decisions, clinical trial results, research collaborations, and market expansion efforts. Our curated news collection covers essential developments including movement disorder therapies like Ingrezza® for tardive dyskinesia, endocrine disorder treatments, and emerging pipeline candidates in neuropsychiatry.
Key focus areas include updates on late-stage clinical programs, partnership announcements with academic institutions, and analyses of therapeutic innovations targeting conditions from Huntington's disease chorea to congenital adrenal hyperplasia. All content is rigorously sourced to ensure accuracy and relevance for both professional investors and medical stakeholders.
Bookmark this page for centralized access to Neurocrine Biosciences' latest scientific advancements, financial disclosures, and treatment development progress. Check regularly for objective reporting on one of biopharma's most innovative neuroscience-focused enterprises.
Neurocrine Biosciences (NBIX) reported Q1 2022 net product sales of $303 million for INGREZZA, marking a 32% increase year-over-year. Total revenues reached $310.6 million, up from $236.6 million a year earlier. The company reiterated its full-year sales guidance for INGREZZA between $1.25 - $1.35 billion, anticipating 20% growth. GAAP net income was $13.9 million, down from $32.1 million in Q1 2021. Increased R&D and SG&A expenses were noted, correlating with expanded clinical programs and salesforce efforts.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 11:20 a.m. PT in Las Vegas. CEO Kevin Gorman and CFO Matt Abernethy will represent the company. The presentation will be available via live webcast on the company's website, with a replay accessible after one hour post-event for about a month. Neurocrine focuses on developing treatments for neurological and neuropsychiatric disorders, with a range of FDA-approved therapies and ongoing clinical programs.
Neurocrine Biosciences (Nasdaq: NBIX) announced its first quarter 2022 financial results conference call and webcast scheduled for May 4, 2022, at 5:00 a.m. PT (8:00 a.m. ET). The Q1 2022 press release will be made available at 4:30 a.m. PT (7:30 a.m. ET) on the same day. Investors can join via a domestic dial-in number (800-895-3361) or international dial-in number (785-424-1062), using the conference ID: NBIX. The webcast link will be accessible on the Neurocrine Biosciences website, with a replay available for one month.
Neurocrine Biosciences announced that valbenazine met its primary endpoint in the Phase 3 KINECT-HD study, showing a significant improvement in chorea severity in Huntington disease patients compared to placebo (p<0.0001). Improvements were evident as early as Week 2. Response rates for clinical and patient global impressions also favored valbenazine. The company plans to submit a supplemental new drug application to the FDA in 2022. The safety profile was consistent with prior studies, with no serious adverse events reported.
Neurocrine Biosciences (Nasdaq: NBIX) announced on March 28, 2022, that its collaboration partner, Mitsubishi Tanabe Pharma Corporation, received regulatory approval from the Japanese Ministry of Health for DYSVAL® (valbenazine) capsules 40 mg, aimed at treating tardive dyskinesia (TD). This approval signifies a key milestone in their partnership established in March 2015, under which MTPC covers all costs related to development and commercialization in Japan and select Asian markets. Neurocrine will earn tiered royalties on future sales, bolstering its financial outlook.
Neurocrine Biosciences (Nasdaq: NBIX) will present new research on treatment patterns and unmet needs for congenital adrenal hyperplasia (CAH) at the AMCP 2022 annual meeting in Chicago from March 29 to April 1. The studies highlight the challenges in managing classic CAH, for which no non-steroidal FDA-approved treatments exist. Current treatment relies on glucocorticoids, posing risks of complications. The company is developing crinecerfont, a non-steroidal CRF1 receptor antagonist, advancing two Phase 3 studies for both adults and children with classic CAH.
Neurocrine Biosciences (Nasdaq: NBIX) announced the presentation of its movement disorders program and telemedicine research at the AAN Annual Meeting from April 2-7, 2022, in Seattle. The research reveals a significant gap in evidence regarding telemedicine's effects on individuals with serious mental illnesses and movement disorders, indicating the need for further studies. The company will also showcase data on INGREZZA (valbenazine) and ONGENTYS (opicapone) in treating tardive dyskinesia and Parkinson's disease, respectively, highlighting ongoing commitments to patient care and treatment outcomes.
Neurocrine Biosciences will present at the Stifel 2022 CNS Days virtual conference on March 28, 2022, at 3:30 p.m. Eastern Time. The presentation will be led by Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer. Attendees can access the live webcast on the company's website under the Investors section. A replay will be available about one hour post-event and archived for a month. Neurocrine specializes in therapies for neurological and neuroendocrine disorders, with an array of FDA-approved treatments and clinical programs.
Neurocrine Biosciences (Nasdaq: NBIX) announced participation in upcoming investor conferences. CEO Kevin Gorman will present at the Cowen 42nd Annual Virtual Health Care Conference on March 8, 2022, at 9:10 a.m. ET. He and CFO Matt Abernethy will also present at the Barclays Global Healthcare Conference on March 16, 2022, at 3:50 p.m. ET in Miami. Additionally, Kyle Gano will speak at the 1st Annual Needham Virtual Neuroscience Forum on the same day at 1:50 p.m. ET. Webcasts will be available on the company's website.
Neurocrine Biosciences (NBIX) reported strong financial results for Q4 and fiscal year 2021, with total revenues of $1.133 billion, up from $1.046 billion in 2020. The company achieved net product sales of $1.1 billion for INGREZZA, reflecting 25% growth in Q4 year-over-year. Despite a GAAP net loss of $7 million in Q4, its non-GAAP net income was $4.3 million. For 2022, NBIX guided INGREZZA sales between $1.25 billion and $1.35 billion, indicating approximately 20% growth. The firm is advancing a diverse pipeline with 12 mid-to-late-stage clinical programs.